HRP20192052T1 - Protutijela anti-siglec-8 te njihovi postupci i uporabe - Google Patents
Protutijela anti-siglec-8 te njihovi postupci i uporabe Download PDFInfo
- Publication number
- HRP20192052T1 HRP20192052T1 HRP20192052TT HRP20192052T HRP20192052T1 HR P20192052 T1 HRP20192052 T1 HR P20192052T1 HR P20192052T T HRP20192052T T HR P20192052TT HR P20192052 T HRP20192052 T HR P20192052T HR P20192052 T1 HRP20192052 T1 HR P20192052T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- region
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 210000004027 cell Anatomy 0.000 claims 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 101000863884 Homo sapiens Sialic acid-binding Ig-like lectin 8 Proteins 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 229930182474 N-glycoside Natural products 0.000 claims 3
- 150000001720 carbohydrates Chemical group 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 2
- 102100029964 Sialic acid-binding Ig-like lectin 8 Human genes 0.000 claims 2
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 2
- 208000030961 allergic reaction Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 208000000592 Nasal Polyps Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010052568 Urticaria chronic Diseases 0.000 claims 1
- 206010046751 Urticaria physical Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 claims 1
- 208000024376 chronic urticaria Diseases 0.000 claims 1
- 206010009869 cold urticaria Diseases 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 101150023212 fut8 gene Proteins 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 102000051056 human SIGLEC8 Human genes 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 201000002881 physical urticaria Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (22)
1. Humanizirano protutijelo koje se veže na humani Siglec-8, naznačeno time, da protutijelo obuhvaća varijabilno područje teškog lanca i varijabilno područje lakog lanca, pri čemu
(i) varijabilno područje teškog lanca sadrži aminokiselinski slijed od SEQ ID NO:6 a varijabilno područje lakog lanca sadrži sadrži aminokiselinski slijed od SEQ ID NO:16 ili SEQ ID NO:21;
ili (ii)
(a) varijabilno područje teškog lanca sadrži:
(1) HC-FR1 koji sadrži aminokiselinski slijed od SEQ ID NO:26;
(2) HVR-H1 koji sadrži aminokiselinski slijed od SEQ ID NO:61;
(3) HC-FR2 koji sadrži aminokiselinski slijed od SEQ ID NO:34;
(4) HVR-H2 koji sadrži aminokiselinski slijed od SEQ ID NO:62;
(5) HC-FR3 koji sadrži aminokiselinski slijed od SEQ ID NO:38;
(6) HVR-H3 koji sadrži aminokiselinski slijed od SEQ ID NO:63; i
(7) HC-FR4 koji sadrži aminokiselinski slijed od SEQ ID NO:45;
i
(b) varijabilno područje lakog lanca koje sadrži:
(1) LC-FR1 koji sadrži aminokiselinski slijed od SEQ ID NO:48;
(2) HVR-L1 koji sadrži aminokiselinski slijed od SEQ ID NO:64;
(3) LC-FR2 koji sadrži aminokiselinski slijed od SEQ ID NO:51;
(4) HVR-L2 koji sadrži aminokiselinski slijed od SEQ ID NO:65;
(5) LC-FR3 koji sadrži aminokiselinski slijed od SEQ ID NO:55 ili 58;
(6) HVR-L3 koji sadrži aminokiselinski slijed od SEQ ID NO:66; i
(7) LC-FR4 koji sadrži aminokiselinski slijed od SEQ ID NO:60.
2. Protutijelo prema patentnom zahtjevu 1(i), naznačeno time, da protutijelo obuhvaća Fc područje teškog lanca koje sadrži humano IgG Fc područje.
3. Protutijelo prema patentnom zahtjevu 2, naznačeno time, da humano IgG Fc područje je humano IgG1 Fc područje ili humano IgG4 Fc područje.
4. Protutijelo prema patentnom zahtjevu 3, naznačeno time, da humani IgG4 obuhvaća aminokiselinsku supstituciju S228P, a ostaci su numerirani u skladu s EU indeksom u Kabat-sustavu numeriranja.
5. Protutijelo prema patentnom zahtjevu 1(i), naznačeno time, da teški lanac sadrži aminokiselinski slijed od SEQ ID NO:75 ili SEQ ID NO:87, a laki lanac sadrži aminokiselinski slijed od SEQ ID NO:76.
6. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačeno time, da protutijelo obuhvaća najmanje jednu aminokiselinsku supstituciju u Fc području koja poboljšava aktivitet citotoksičnosti posredstvom stanice u ovisnosti o protutijelu (ADCC - engl. antibody-dependent cell-mediated cytotoxicity).
7. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačeno time, da je jedan ili su dva teška lanca protutjela ne-fukoziliran(a).
8. Nukleinska kiselina, naznačena time, da kodira protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 7.
9. Vektor, naznačen time, da obuhvaća nukleinsku kiselinu prema patentnom zahtjevu 8.
10. Izolirana stanica domaćina, naznačena time, da obuhvaća nukleinsku kiselinu prema patentnom zahtjevu 8.
11. Izolirana stanica domaćina prema patentnom zahtjevu 10, naznačena time, da stanica domaćina predstavlja staničnu liniju s izbacivanjem gena alfa1,6-fukoziltransferaze (Fut8) ili staničnu liniju koja prekomjerno izražava ß1,4-N-acetilglukoziminiltransferazu III (GnT-III).
12. Izolirana stanica domaćina prema patentnom zahtjevu 11, naznačena time, da stanična linija dodatno prekomjerno izražava Golgi μ-manosidazu II (ManII).
13. Postupak proizvodnje protutijela, naznačen time, da obuhvaća kultiviranje stanice domaćina u skladu s bilo kojim od patentnih zahtjeva 10 do 12, pod uvjetima koji proizvode protutijelo.
14. Protutijelo anti-Siglec-8, naznačeno time, da se proizvodi putem postupka koji obuhvaća kultiviranje stanice domaćina koja sadrži nukleinsku kiselinu prema patentnom zahtjevu 8, ili kultiviranje stanice domaćina u skladu s bilo kojim od patentnih zahtjeva 10 do 12, pod uvjetima koji proizvode protutijelo, pri čemu stanica domaćina je stanica sisavca.
15. Pripravak, naznačen time, da obuhvaća protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 7 i 14, pri čemu protutijelo obuhvaća Fc područje i na to Fc područje povezane ugljikohidratne lance koji su povezani s N-glikozidom, gdje manje od 50% ugljikohidratnih lanaca koji su povezani s N-glikozidom, sadrži ostatak fukoze.
16. Pripravak prema patentnom zahtjevu 15, naznačen time, da u biti niti jedan od ugljikohidratnih lanaca koji su povezani s N-glikozidom, ne sadrži ostatak fukoze.
17. Farmaceutski pripravak, naznačen time, da obuhvaća protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 7 i 14, i farmaceutski prihvatljiv nosač.
18. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 7 i 14 ili pripravak u skladu s bilo kojim od patentnih zahtjeva 15 do 17, naznačeni time, da se upotrebljavaju u postupku liječenja.
19. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 7 i 14 ili pripravak u skladu s bilo kojim od patentnih zahtjeva 15 do 17, naznačeni time, da se upotrebljavaju u postupku liječenja bolesti koja je odabrana iz skupine koja se sastoji od sljedećih: astma, alergijski rinitis, nosni polipi, atopijski dermatitis, kronična urtikarija, mastocitoza, eozinofilna leukemija, hipereozinofilni sindrom, astma s pomanjkanjem granulocita, akutna ili kronična hipersenzibilnost dišnih puteva, eozinofilni ezofagitis, Churg-Straussov sindrom, fizikalna urtikarija, hladna urtikarija, tlačna utrikarija, bulozni pemfigoid, alergija na hranu, i alergijska bronhopulmonarna aspergiloza (ABPA).
20. Protutijelo za uporabu ili pripravak za uporabu u skladu s patentnim zahtjevom 18, naznačeni time, da protutijelo ili pripravak inhibiraju jedan ili više simptoma alergijske reakcije, pri čemu je alergijska reakcija opcionalno jedna hipersenzitivna reakcija Tipa I.
21. Protutijelo za uporabu ili pripravak za uporabu u skladu s patentnim zahtjevom 18, naznačeni time, da postupak liječenja uključuje iscrpljivanje mastocita koji eksprimiraju Siglec-8, pomoću ADCC-akiviteta.
22. Protutijelo za uporabu ili pripravak za uporabu u skladu s patentnim zahtjevom 18, naznačeni time, da postupak liječenja uključuje iscrpljivanje eozinofila koji eksprimiraju Siglec-8, pomoću ADCC-akiviteta.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913891P | 2013-12-09 | 2013-12-09 | |
| EP14869424.3A EP3079719B8 (en) | 2013-12-09 | 2014-12-09 | Anti-siglec-8 antibodies and methods of use thereof |
| PCT/US2014/069409 WO2015089117A1 (en) | 2013-12-09 | 2014-12-09 | Anti-siglec-8 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192052T1 true HRP20192052T1 (hr) | 2020-02-07 |
Family
ID=53371783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192052TT HRP20192052T1 (hr) | 2013-12-09 | 2019-11-13 | Protutijela anti-siglec-8 te njihovi postupci i uporabe |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US9546215B2 (hr) |
| EP (2) | EP3079719B8 (hr) |
| JP (4) | JP6549143B2 (hr) |
| KR (3) | KR102311761B1 (hr) |
| CN (3) | CN105916519B (hr) |
| AU (2) | AU2014363944B2 (hr) |
| BR (1) | BR112016013109B1 (hr) |
| CA (1) | CA2930886C (hr) |
| CY (1) | CY1122329T1 (hr) |
| DK (1) | DK3079719T3 (hr) |
| ES (1) | ES2758508T3 (hr) |
| HR (1) | HRP20192052T1 (hr) |
| HU (1) | HUE047283T2 (hr) |
| IL (3) | IL298470A (hr) |
| LT (1) | LT3079719T (hr) |
| NZ (1) | NZ720769A (hr) |
| PL (1) | PL3079719T3 (hr) |
| PT (1) | PT3079719T (hr) |
| RS (1) | RS59567B1 (hr) |
| SG (2) | SG11201604632PA (hr) |
| SI (1) | SI3079719T1 (hr) |
| WO (1) | WO2015089117A1 (hr) |
| ZA (1) | ZA201603435B (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4014995A1 (en) * | 2014-02-28 | 2022-06-22 | Allakos Inc. | Methods and compositions for treating siglec-8 associated diseases |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| CA2987797A1 (en) * | 2015-06-17 | 2016-12-22 | Christopher Robert Bebbington | Methods and compositions for treating fibrotic diseases |
| US10604577B2 (en) * | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| JP2020504135A (ja) * | 2017-01-06 | 2020-02-06 | アラコス インコーポレイテッド | 慢性閉塞性肺障害を処置するための方法および組成物 |
| SG10202112259VA (en) * | 2017-05-05 | 2021-12-30 | Allakos Inc | Methods and compositions for treating inflammatory gastrointestinal disorders |
| US11203638B2 (en) * | 2017-05-05 | 2021-12-21 | Allakos Inc. | Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis |
| KR20210005245A (ko) * | 2018-05-04 | 2021-01-13 | 알라코스 인크. | 만성 두드러기를 치료하기 위한 방법 및 조성물 |
| SG11202108833QA (en) * | 2019-02-15 | 2021-09-29 | Allakos Inc | Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis |
| JP2022542472A (ja) * | 2019-08-02 | 2022-10-03 | アラコス インコーポレイテッド | 抗ｓｉｇｌｅｃ－８抗体および副腎皮質ステロイド薬を投与する方法 |
| JP2022553378A (ja) * | 2019-10-24 | 2022-12-22 | アラコス インコーポレイテッド | 過敏性腸症候群および機能性ディスペプシアを処置するための方法および組成物 |
| CA3158364A1 (en) * | 2019-11-19 | 2021-05-27 | The Trustees Of The University Of Pennsylvania | Anti-alpha-synuclein monoclonal antibodies, and methods using same |
| US20230210989A1 (en) * | 2020-06-03 | 2023-07-06 | Kar Muthumani | Monoclonal Antibody Against Human Siglec-9 and Use For Immunotherapy |
| WO2022061032A1 (en) * | 2020-09-17 | 2022-03-24 | Allakos Inc. | Methods and compositions for treating viral infection |
| JPWO2022215566A1 (hr) * | 2021-04-05 | 2022-10-13 | ||
| WO2023215907A1 (en) * | 2022-05-06 | 2023-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Inhibiting mast cell activation by binding sialic acid-binding immunoglobulin-like lectin-9 (siglec-9) |
| WO2024043940A1 (en) * | 2022-08-25 | 2024-02-29 | Allakos Inc. | Methods and compositions for treating atopic dermatitis |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
| JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用 |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| WO1997038123A1 (en) | 1996-04-05 | 1997-10-16 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
| CA2307166A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2340112T3 (es) | 1998-04-20 | 2010-05-28 | Glycart Biotechnology Ag | Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos. |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2278003B2 (en) | 1999-04-09 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| WO2001029246A1 (fr) | 1999-10-19 | 2001-04-26 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production d'un polypeptide |
| US20030092091A1 (en) | 2000-03-07 | 2003-05-15 | Abrahamson Julie A. | Sialoadhesin factor-2 antibodies |
| ES2431834T3 (es) * | 2000-03-07 | 2013-11-28 | The Johns Hopkins University | Anticuerpos de sialoadhesina factor-2 |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| DE60143544D1 (de) | 2000-12-12 | 2011-01-05 | Medimmune Llc | Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung |
| PL217751B1 (pl) | 2001-08-03 | 2014-08-29 | Glycart Biotechnology Ag | Zastosowanie glikomodyfikowanego przeciwciała do wytwarzania kompozycji farmaceutycznej do leczenia choroby wybranej z grupy składającej się z nowotworu, małopłytkowości autoimmunologicznej w przewlekłej chorobie przeszczep przeciwko gospodarzowi i immunozależnej nabytej aplazji czysto czerwonokrwinkowej |
| AU2002337935B2 (en) * | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
| EP1502603A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM |
| CA2481656A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| SG2013036975A (en) | 2002-12-16 | 2016-07-28 | Genentech Inc | Immunoglobulin variants and uses thereof |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| NZ588860A (en) | 2003-11-05 | 2012-03-30 | Roche Glycart Ag | CD20 antibodies with increased Fc receptor binding affinity and effector function |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| AU2005207003C1 (en) | 2004-01-20 | 2013-06-13 | Humanigen, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| WO2005116088A2 (en) | 2004-05-25 | 2005-12-08 | The Johns Hopkins University | Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells |
| CA2587158C (en) | 2004-11-16 | 2016-01-12 | Kalobios, Inc. | Immunoglobulin variable region cassette exchange |
| EP1951740B1 (en) | 2005-11-10 | 2014-07-16 | James Paulson | High affinity siglec ligands |
| US20070134259A1 (en) | 2005-11-21 | 2007-06-14 | David Bundle | Methods and compositions for pharmacologially controlled targeted immunotherapy |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| PL2282773T3 (pl) | 2008-05-02 | 2014-08-29 | Seattle Genetics Inc | Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej |
| IN2012DN01769A (hr) * | 2009-08-28 | 2015-06-05 | Vlst Corp | |
| EA026336B1 (ru) | 2009-09-22 | 2017-03-31 | Пробиоген Аг | Клетка позвоночного или насекомого для продукции белка или липида, не содержащего фукозу или содержащего сниженное количество фукозы, и ее применения |
| US8586044B2 (en) | 2010-05-28 | 2013-11-19 | Northwestern University | Treatment of chronic pelvic pain syndrome |
| EP2465873A1 (en) | 2010-12-16 | 2012-06-20 | Deutsches Rheuma-Forschungszentrum Berlin | Eosinophils as a therapeutic target |
| SG192632A1 (en) * | 2011-03-06 | 2013-09-30 | Merck Serono Sa | Low fucose cell lines and uses thereof |
| JP6282232B2 (ja) * | 2012-02-10 | 2018-02-21 | ユニバーシティー オブ メリーランド，ボルティモア | 抗体及びそのＦｃフラグメントの酵素化学的糖鎖改変 |
| EP4014995A1 (en) * | 2014-02-28 | 2022-06-22 | Allakos Inc. | Methods and compositions for treating siglec-8 associated diseases |
| US10604577B2 (en) * | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
| US11203638B2 (en) * | 2017-05-05 | 2021-12-21 | Allakos Inc. | Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis |
-
2014
- 2014-12-09 WO PCT/US2014/069409 patent/WO2015089117A1/en active Application Filing
- 2014-12-09 PL PL14869424T patent/PL3079719T3/pl unknown
- 2014-12-09 AU AU2014363944A patent/AU2014363944B2/en active Active
- 2014-12-09 CA CA2930886A patent/CA2930886C/en active Active
- 2014-12-09 DK DK14869424T patent/DK3079719T3/da active
- 2014-12-09 CN CN201480067583.8A patent/CN105916519B/zh active Active
- 2014-12-09 JP JP2016557547A patent/JP6549143B2/ja active Active
- 2014-12-09 IL IL298470A patent/IL298470A/en unknown
- 2014-12-09 HU HUE14869424A patent/HUE047283T2/hu unknown
- 2014-12-09 CN CN202111165415.0A patent/CN114044825A/zh active Pending
- 2014-12-09 CN CN202111165428.8A patent/CN113861293A/zh active Pending
- 2014-12-09 SG SG11201604632PA patent/SG11201604632PA/en unknown
- 2014-12-09 EP EP14869424.3A patent/EP3079719B8/en active Active
- 2014-12-09 SG SG10201808835QA patent/SG10201808835QA/en unknown
- 2014-12-09 NZ NZ720769A patent/NZ720769A/en unknown
- 2014-12-09 EP EP19186014.7A patent/EP3611191A1/en active Pending
- 2014-12-09 KR KR1020167018130A patent/KR102311761B1/ko active IP Right Grant
- 2014-12-09 BR BR112016013109-6A patent/BR112016013109B1/pt active IP Right Grant
- 2014-12-09 ES ES14869424T patent/ES2758508T3/es active Active
- 2014-12-09 KR KR1020217032002A patent/KR20210125114A/ko not_active IP Right Cessation
- 2014-12-09 SI SI201431406T patent/SI3079719T1/sl unknown
- 2014-12-09 US US14/565,370 patent/US9546215B2/en active Active
- 2014-12-09 PT PT148694243T patent/PT3079719T/pt unknown
- 2014-12-09 LT LT14869424T patent/LT3079719T/lt unknown
- 2014-12-09 KR KR1020237021876A patent/KR20230107382A/ko not_active Application Discontinuation
- 2014-12-09 RS RS20191504A patent/RS59567B1/sr unknown
-
2016
- 2016-05-16 IL IL245663A patent/IL245663B/en active IP Right Grant
- 2016-05-19 ZA ZA2016/03435A patent/ZA201603435B/en unknown
- 2016-12-07 US US15/372,268 patent/US20170209556A1/en not_active Abandoned
-
2019
- 2019-02-15 JP JP2019025337A patent/JP6963577B2/ja active Active
- 2019-05-17 US US16/416,085 patent/US20200054723A1/en not_active Abandoned
- 2019-11-13 HR HRP20192052TT patent/HRP20192052T1/hr unknown
- 2019-11-27 CY CY20191101242T patent/CY1122329T1/el unknown
-
2020
- 2020-02-25 JP JP2020029472A patent/JP2020078336A/ja not_active Withdrawn
- 2020-06-16 AU AU2020204016A patent/AU2020204016A1/en not_active Abandoned
-
2021
- 2021-01-13 IL IL280155A patent/IL280155A/en unknown
-
2022
- 2022-01-26 US US17/585,323 patent/US20220331412A1/en not_active Abandoned
- 2022-04-06 JP JP2022063368A patent/JP2022082715A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192052T1 (hr) | Protutijela anti-siglec-8 te njihovi postupci i uporabe | |
| KR102140113B1 (ko) | 인간 호흡기 세포융합 바이러스를 중화시키는 항체 | |
| HRP20221141T1 (hr) | Anti-lag3 protutijela | |
| RU2017119543A (ru) | Анти-tim3 антитела и способы их применения | |
| JP2018085988A5 (hr) | ||
| JP2014508759A5 (hr) | ||
| JP2012107050A5 (hr) | ||
| JP2013544492A5 (hr) | ||
| JP2017536102A5 (hr) | ||
| RU2016106101A (ru) | АФУКОЗИЛИРОВАННЫЕ АНТИТЕЛА К РЕЦЕПТОРУ ФАКТОРА РОСТА ФИБРОБЛАСТОВ FGFR2IIIb | |
| Zeitlin et al. | Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model | |
| US8663950B2 (en) | Production of a monoclonal antibody therapeutic against west nile virus in plants | |
| RU2014130766A (ru) | Гуманизированное анти-эпирегулин-антитело и противораковый терапевтический агент, содержащий указанное антитело, в качестве активного ингредиента | |
| CN109232738B (zh) | 一种抗人ox40单克隆抗体及其应用 | |
| JP2018535648A5 (hr) | ||
| EP3851456A1 (en) | Anti-cd38 antibody, antigen-binding fragment thereof, and pharmaceutical use | |
| JP2014508511A5 (hr) | ||
| JP2013539962A5 (hr) | ||
| JPWO2020214995A5 (hr) | ||
| WO2020251834A1 (en) | Antibodies and methods for treatment of viral infections | |
| US20220372114A1 (en) | Sars-cov-2 spike protein antibodies | |
| WO2024068996A1 (en) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection | |
| NZ741129B2 (en) | Anti-pd1 antibodies and methods of use | |
| EA039222B1 (ru) | Антитело, нейтрализующее респираторно-синцитиальный вирус человека | |
| NZ624650A (en) | Purification of anti-c-met antibodies |